Published online before print July 8, 2002, doi: 10.1161/01.RES.0000028149.15986.4C
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2002 American Heart Association, Inc.
Molecular Medicine |
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Interfere With Angiogenesis by Inhibiting the Geranylgeranylation of RhoA
From the Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (H.-J.P., D.K., U.B., D.T. J.B.G.), Boston, Mass, and the Department of Molecular, Cell and Developmental Biology and Molecular Biology Institute (L.I.-A.), University of California at Los Angeles.
Correspondence to Dr Jonas B. Galper, Department of Medicine, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail Galper{at}calvin.bwh.harvard.edu
Angiogenesis is implicated in the pathogenesis of cancer, rheumatoid arthritis, and atherosclerosis and in the treatment of coronary artery and peripheral vascular disease. Here, cholesterol-lowering agents, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are shown to interfere with angiogenesis. In vivo, the HMG-CoA reductase inhibitor simvastatin dose-dependently inhibited capillary growth in both vascular endothelial growth factor–stimulated chick chorioallantoic membranes and basic fibroblast growth factor–stimulated mouse corneas. In vitro, the development of tubelike structures by human microvascular endothelial cells cultured on 3D collagen gels was inhibited at simvastatin concentrations similar to those found in the serum of patients on therapeutic doses of this agent. HMG-CoA reductase inhibitors interfered with angiogenesis via inhibition of the geranylgeranylation and membrane localization of RhoA. Simvastatin inhibited membrane localization of RhoA with a concentration dependence similar to that for the inhibition of tube formation, whereas geranylgeranyl pyrophosphate, the substrate for the geranylgeranylation of Rho, reversed the effect of simvastatin on tube formation and on the membrane localization of RhoA. Furthermore, tube formation was inhibited by GGTI, a specific inhibitor of the geranylgeranylation of Rho; by C3 exotoxin, which inactivates Rho; and by the adenoviral expression of a dominant-negative RhoA mutant. The expression of a dominant-activating RhoA mutant reversed the effect of simvastatin on tube formation. Finally, HMG-CoA reductase inhibitors inhibited signaling by vascular endothelial growth factor, Akt, and focal adhesion kinase, three RhoA-dependent pathways known to be involved in angiogenesis. This study demonstrates a new relationship between lipid metabolism and angiogenesis and an antiangiogenic effect of HMG-CoA reductase inhibitors with possible important therapeutic implications.
Key Words: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors • angiogenesis • RhoA
This article has been cited by other articles:
 |
|
 |
|
  Y. Zhang, J. C. Naggar, C. M. Welzig, D. Beasley, K. S. Moulton, H.-J. Park, and J. B. Galper Simvastatin Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-Knockout Mice: Possible Role of ERK Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1764 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lu, L. Chan, H. D.G. Fiji, R. Dahl, O. Kwon, and F. Tamanoi In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I Mol. Cancer Ther., May 1, 2009; 8(5): 1218 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. van Nieuw Amerongen and V. W. M. van Hinsbergh Role of ROCK I/II in vascular branching Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H903 - H905. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Solomon, K. Pelton, K. Boucher, J. Joo, C. Tully, D. Zurakowski, C. P. Schaffner, J. Kim, and M. R. Freeman Ezetimibe Is an Inhibitor of Tumor Angiogenesis Am. J. Pathol., March 1, 2009; 174(3): 1017 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Boodhwani, S. Mieno, J. Feng, N. R. Sodha, R. T. Clements, S.-H. Xu, and F. W. Sellke Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 117 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Flick, L. A. Habel, K. A. Chan, S. K. Van Den Eeden, V. P. Quinn, R. Haque, E. J. Orav, J. D. Seeger, M. C. Sadler, C. P. Quesenberry Jr., et al. Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2218 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oktem, I. Esinler, D. Eroglu, N. Haberal, N. Bayraktar, and H. B. Zeyneloglu High-dose atorvastatin causes regression of endometriotic implants: a rat model Hum. Reprod., May 1, 2007; 22(5): 1474 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-Y. Zhu, E. Daghini, A. R. Chade, C. Napoli, E. L. Ritman, A. Lerman, and L. O. Lerman Simvastatin Prevents Coronary Microvascular Remodeling in Renovascular Hypertensive Pigs J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1209 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Ahn, G. Sethi, and B. B. Aggarwal Simvastatin Potentiates TNF-{alpha}-Induced Apoptosis through the Down-Regulation of NF-{kappa}B-Dependent Antiapoptotic Gene Products: Role of I{kappa}B{alpha} Kinase and TGF-beta-Activated Kinase-1 J. Immunol., February 15, 2007; 178(4): 2507 - 2516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yao, R.-H. Zhou, M. Petreaca, L. Zheng, J. Shyy, and M. Martins-Green Activation of sterol regulatory element-binding proteins (SREBPs) is critical in IL-8-induced angiogenesis J. Leukoc. Biol., September 1, 2006; 80(3): 608 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. K. Peterson, P. Kelly, C. A. Weinbaum, and P. J. Casey A Novel Protein Geranylgeranyltransferase-I Inhibitor with High Potency, Selectivity, and Cellular Activity J. Biol. Chem., May 5, 2006; 281(18): 12445 - 12450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Byfield, S. Tikku, G. H. Rothblat, K. J. Gooch, and I. Levitan OxLDL increases endothelial stiffness, force generation, and network formation J. Lipid Res., April 1, 2006; 47(4): 715 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard The Role of Statins in Cancer Therapy. Oncologist, January 1, 2006; 11(3): 306 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sen-Banerjee, S. Mir, Z. Lin, A. Hamik, G. B. Atkins, H. Das, P. Banerjee, A. Kumar, and M. K. Jain Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells Circulation, August 2, 2005; 112(5): 720 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ohkawara, T. Ishibashi, T. Sakamoto, K. Sugimoto, K. Nagata, K. Yokoyama, N. Sakamoto, M. Kamioka, I. Matsuoka, S. Fukuhara, et al. Thrombin-induced Rapid Geranylgeranylation of RhoA as an Essential Process for RhoA Activation in Endothelial Cells J. Biol. Chem., March 18, 2005; 280(11): 10182 - 10188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Verhulst, P. C. D'Haese, and M. E. De Broe Inhibitors of HMG-CoA Reductase Reduce Receptor-mediated Endocytosis in Human Kidney Proximal Tubular Cells J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2249 - 2257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Coupel, F. Leboeuf, G. Boulday, J.-P. Soulillou, and B. Charreau RhoA Activation Mediates Phosphatidylinositol 3-Kinase-Dependent Proliferation of Human Vascular Endothelial Cells: An Alloimmune Mechanism of Chronic Allograft Nephropathy J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2429 - 2439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Epstein, E. Stabile, T. Kinnaird, C. W. Lee, L. Clavijo, and M. S. Burnett Janus Phenomenon: The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis Circulation, June 15, 2004; 109(23): 2826 - 2831. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C Larsson, M. Kumlin, M. Ingelman-Sundberg, and A. Wolk Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms Am. J. Clinical Nutrition, June 1, 2004; 79(6): 935 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Liao Statin Therapy: Having the Good Without the Bad Hypertension, June 1, 2004; 43(6): 1171 - 1172. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Keezer, S. E. Ivie, H. C. Krutzsch, A. Tandle, S. K. Libutti, and D. D. Roberts Angiogenesis Inhibitors Target the Endothelial Cell Cytoskeleton through Altered Regulation of Heat Shock Protein 27 and Cofilin Cancer Res., October 1, 2003; 63(19): 6405 - 6412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wolfrum, K. S. Jensen, and J. K. Liao Endothelium-Dependent Effects of Statins Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Moulton, K. Vakili, D. Zurakowski, M. Soliman, C. Butterfield, E. Sylvin, K.-M. Lo, S. Gillies, K. Javaherian, and J. Folkman Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis PNAS, April 15, 2003; 100(8): 4736 - 4741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. van Nieuw Amerongen, P. Koolwijk, A. Versteilen, and V. W.M. van Hinsbergh Involvement of RhoA/Rho Kinase Signaling in VEGF-Induced Endothelial Cell Migration and Angiogenesis In Vitro Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 211 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bea, E. Blessing, B. Bennett, M. Levitz, E. P. Wallace, and M. E. Rosenfeld Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1832 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.S. MOULTON Plaque Angiogenesis: Its Functions and Regulation Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 471 - 482. [Abstract] [PDF]
|
|